These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28711390)

  • 1. Liraglutide preserves renal function in overweight diabetic patients with stage 3 chronic kidney disease.
    de Lucas MDG; Bueno BA; Sierra JO
    Eur J Intern Med; 2017 Oct; 44():e28-e29. PubMed ID: 28711390
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials.
    von Scholten BJ; Davies MJ; Persson F; Hansen TW; Madsbad S; Endahl L; Jepsen CH; Rossing P
    J Diabetes Complications; 2017 Jul; 31(7):1164-1168. PubMed ID: 28462892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Tonneijck L; Smits MM; Muskiet MH; Hoekstra T; Kramer MH; Danser AH; Ter Wee PM; Diamant M; Joles JA; van Raalte DH
    Diabetes Care; 2016 Nov; 39(11):2042-2050. PubMed ID: 27585605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes.
    von Scholten BJ; Hansen TW; Goetze JP; Persson F; Rossing P
    J Diabetes Complications; 2015 Jul; 29(5):670-4. PubMed ID: 25935863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.
    Garvey WT; Birkenfeld AL; Dicker D; Mingrone G; Pedersen SD; Satylganova A; Skovgaard D; Sugimoto D; Jensen C; Mosenzon O
    Diabetes Care; 2020 May; 43(5):1085-1093. PubMed ID: 32139381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor.
    de Luis DA; Diaz Soto G; Izaola O; Romero E
    J Diabetes Complications; 2015; 29(4):595-8. PubMed ID: 25825013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exposure-response analyses of liraglutide 3.0 mg for weight management.
    Wilding JP; Overgaard RV; Jacobsen LV; Jensen CB; le Roux CW
    Diabetes Obes Metab; 2016 May; 18(5):491-9. PubMed ID: 26833744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effectiveness of liraglutide vs basal insulin in a real-world setting: Evidence of improved glycaemic and weight control in obese people with type 2 diabetes.
    Overbeek JA; Heintjes EM; Huisman EL; Tikkanen CK; van Diermen AW; Penning-van Beest FJA; Herings RMC
    Diabetes Obes Metab; 2018 Sep; 20(9):2093-2102. PubMed ID: 29726082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial.
    Idorn T; Knop FK; Jørgensen MB; Jensen T; Resuli M; Hansen PM; Christensen KB; Holst JJ; Hornum M; Feldt-Rasmussen B
    Diabetes Care; 2016 Feb; 39(2):206-13. PubMed ID: 26283739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment.
    Zobel EH; von Scholten BJ; Lindhardt M; Persson F; Hansen TW; Rossing P
    J Diabetes Complications; 2017 Jan; 31(1):162-168. PubMed ID: 27769801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes.
    Dubé MC; D'Amours M; Weisnagel SJ
    Diabetes Obes Metab; 2018 Jan; 20(1):178-184. PubMed ID: 28722271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
    Guo W; Tian W; Lin L; Xu X
    Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Annual deterioration of renal function in hypertensive patients with and without diabetes.
    Polonia J; Azevedo A; Monte M; Silva JA; Bertoquini S
    Vasc Health Risk Manag; 2017; 13():231-237. PubMed ID: 28721063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication.
    von Scholten BJ; Ørsted DD; Svendsen AL; Persson F; Rossing P
    J Diabetes Complications; 2015; 29(8):1146-51. PubMed ID: 26345339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.
    Lane W; Weinrib S; Rappaport J
    Diabetes Technol Ther; 2011 May; 13(5):592-5. PubMed ID: 21406014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long Term Effects of Liraglutide in Japanese Patients with type 2 Diabetes Among the Subgroups with Different Renal Functions: Results of 2-Year Prospective Study.
    Hiramatsu T; Ozeki A; Ishikawa H; Furuta S
    Drug Res (Stuttg); 2017 Nov; 67(11):640-646. PubMed ID: 28738426
    [No Abstract]   [Full Text] [Related]  

  • 17. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial).
    Lind M; Hirsch IB; Tuomilehto J; Dahlqvist S; Ahrén B; Torffvit O; Attvall S; Ekelund M; Filipsson K; Tengmark BO; Sjöberg S; Pehrsson NG
    BMJ; 2015 Oct; 351():h5364. PubMed ID: 26512041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.
    Gough SC; Bode BW; Woo VC; Rodbard HW; Linjawi S; Zacho M; Reiter PD; Buse JB
    Diabetes Obes Metab; 2015 Oct; 17(10):965-73. PubMed ID: 25980900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery.
    Gorgojo-Martínez JJ; Feo-Ortega G; Serrano-Moreno C
    Surg Obes Relat Dis; 2016 Dec; 12(10):1856-1863. PubMed ID: 27256860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide for the Treatment of Type 2 Diabetes and Safety in Diabetic Kidney Disease: Liraglutide and Diabetic Kidney Disease.
    Cherney DZ; Tuttle KR
    Clin J Am Soc Nephrol; 2020 Apr; 15(4):444-446. PubMed ID: 32149722
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.